RxDoctor Payments Data

Michael Seropyan

Psychiatric/Mental Health · Sunny Isles Beach, FLNPI 1386163053

Payments from drug & device makers

$4,330in general payments, 2019–2025

Across 125 payments — averaging $34.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$997
  • Otsuka America Pharmaceutical, Inc.$934
  • Lundbeck LLC$494
  • Vanda Pharmaceuticals Inc.$384
  • Teva Pharmaceuticals USA, Inc.$371
  • Alkermes, Inc.$194
  • plus $956 from 12 others

What the payments were for

  • Food & beverage$4,330100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,330 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$113,685
Medicare patients
98
Services billed
1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole29$40,464
LybalviOlanzapine/Samidorphan Malate13$19,060
VraylarCariprazine Hcl13$18,214
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl63$14,107
TrintellixVortioxetine Hydrobromide20$9,077
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$8,735
LamictalLamotrigine12$8,680
CymbaltaDuloxetine Hcl24$6,264
RitalinMethylphenidate Hcl15$3,759
Doxepin Hcl73$3,468
Lurasidone Hcl34$3,340
Mirtazapine295$3,034
Quetiapine Fumarate424$2,931
Clonazepam393$2,568
Bupropion XlBupropion Hcl138$2,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$934$40,46429 claims
Alkermes, Inc.Lybalvi$194$19,06013 claims
AbbVieVraylar$997$18,21413 claims
Orexo US, Inc.Zubsolv$38$8,73513 claims
Almatica Pharma LLCSertraline Hcl$81$493223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Sunny Isles Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →